What Endalis does

Endalis is a privately held French medical device company founded in 2007 and headquartered in Brignais (Lyon), France, with an Asia-Pacific hub in Seoul, South Korea. The company designs and manufactures the End-Ball intragastric balloon system, a non-surgical weight loss device placed endoscopically under sedation and removed after a six-month treatment course. Endalis claims a proprietary air-liquid filling system as the technical differentiator versus traditional liquid- or gas-only balloons, with cited clinical outcomes of approximately 16 kg weight loss over six months, 20% total body weight reduction when combined with GLP-1 therapy, and reductions in HbA1c, blood pressure, LDL cholesterol, and sleep apnea severity.

Endalis monetizes through sale of the End-Ball device to authorized medical facilities and through the broader six-month treatment program (placement, multidisciplinary follow-up every 4–6 weeks, and removal). The go-to-market is consultative and clinically driven: board-certified gastroenterologists and bariatric specialists serve as the prescribing channel, supported by regional training and patient inquiry handling (including WhatsApp). The company is ISO 13485 certified and has secured regulatory clearances across Europe (CE via GMED), South Korea (KGMP/MFDS), Sri Lanka (NMRA), Canada (MDEL Class II), the Middle East (SFDA/AMAR/MoH), Africa (PPB/MoH/ANDPM), and Latin America (ARCSA/DIGEMAPS/COFEPRIS), with an FDA 510(k)/De Novo submission in progress targeting US approval in 2026.

Name

Endalis

Legal name

Endalis

Website

https://endalis.com

Company type

Private

Founded year

2007

Operating status

Operating

Headcount range

1–10 employees

Short description

Endalis is a French medical device company that designs and manufactures the End-Ball intragastric balloon, a non-surgical weight loss solution sold to clinics and prescribed by gastroenterologists for adults with BMI 27–40 across 15+ certified countries.

Ownership category

akta.pro rank

Headquarters

HQ city

Brignais

HQ country

France

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Gastric Balloon Device Sales: Sale of Endalis gastric balloon devices to healthcare providers and medical facilities for weight loss treatment programs
2. Medical Treatment Programs: Revenue generated from comprehensive 6-month treatment programs including balloon placement, ongoing monitoring consultations, and removal procedure

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Core offering

Endalis develops, manufactures, and markets the End-Ball intragastric balloon, a non-surgical weight-loss medical device engineered and produced in France. The device employs a proprietary air-liquid filling system, is placed endoscopically in the stomach to occupy space and promote satiety, and is removed after six months. The product is offered through authorized medical providers as part of a clinically supervised weight-loss program, with international availability in 15+ countries.

Product overview

Endalis offers the End-Ball gastric balloon system as its core product — a non-surgical weight loss solution designed and manufactured in France. The End-Ball is an intragastric balloon that is endoscopically inserted into the stomach, occupying space to create a sensation of fullness and reduce food intake naturally. The company also provides combined therapy protocols that integrate GLP-1 receptor agonists (such as semaglutide and liraglutide) with the balloon treatment for enhanced weight loss outcomes.

Differentiator

Problem solved

Functional benefit

Brands

• End-Ball: Gastric balloon product - a revolutionary non-surgical weight loss solution designed and manufactured in France with air-liquid filling system for appetite reduction and stomach volume reduction.

Products and services

• End-Ball Intragastric Balloon Non-surgical, endoscopically placed gastric balloon device designed for weight loss in patients with elevated BMI. Uses a proprietary air-liquid filling system, is manufactured in France, remains in the stomach for up to six months, and is then removed. Sold to authorized medical facilities and bariatric clinics that perform the procedure and oversee the surrounding clinical program. Reported clinical outcome of approximately 16 kg weight loss over six months.
• Six-Month Bariatric Treatment Program Clinically supervised six-month weight-loss program built around the End-Ball intragastric balloon, combining device placement, follow-up clinical management during the balloon's six-month dwell period, and balloon removal. Offered through authorized medical providers to patients with elevated BMI seeking non-surgical obesity treatment.

Quantifiable outcome

• Average 16kg total body weight loss within first 6-month treatment period
• +7 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered core.

• Korean Research Group for Endoscopic Management of Metabolic Disorder and ObesitycoreStrategic or Co-development PartnerCollaborative research partnership for clinical evidence development. Contributed to efficacy and safety study of intragastric balloons for obesity in Korea published in Clinical Endoscopy 2023.
• Healthcare Professionals (Gastroenterologists)coreImplementation/ SI/ Consulting PartnerNetwork of board-certified gastroenterologists performing Endalis balloon procedures. Includes multidisciplinary teams with nutritionists and psychologists for comprehensive patient care.

Scale indicators7 records

Recent moves2 records

Expansion highlights4 records

Broad incumbents

• Novo Nordisk: Novo Nordisk markets Wegovy and Ozempic (semaglutide), the leading GLP-1 obesity and diabetes drugs. As a broad incumbent in obesity care, it represents both a combination-therapy partner and a potential substitute for procedural balloon treatment.
• ReShape Lifesciences: ReShape markets the ReShape Intragastric Balloon and other minimally invasive weight-loss products. As a broader metabolic and bariatric device incumbent, it competes in the same procedure-based obesity-treatment space as Endalis.
• Apollo Endosurgery: Apollo manufactures the Orbera intragastric balloon and OverStitch endoscopic suturing system. As an established US-listed bariatric endoscopy player, it is a broad incumbent in the same procedure-based obesity-treatment category.
• Medtronic: Medtronic is a large medical-device incumbent offering surgical bariatric and metabolic products. As a broad incumbent in obesity interventions, it provides strategic context on adjacent surgical alternatives to Endalis's endoscopic approach.
• Eli Lilly: Eli Lilly markets Mounjaro/Zepbound (tirzepatide), the leading dual GLP-1/GIP obesity therapy. It is a broad incumbent in obesity care whose pharmacological regimens compete with and could complement End-Ball combination therapy.

Direct peers

• Spatz Medical: Spatz Medical makes the Spatz3 adjustable gastric balloon, a direct intragastric balloon competitor. Its adjustable-volume feature competes with Endalis's air-liquid filling approach in the same BMI 27-40 patient segment.
• Allurion Technologies: Allurion markets the Elipse swallowable, procedure-less gastric balloon for weight loss. It is the most directly comparable intragastric balloon peer, competing head-to-head with End-Ball in non-surgical obesity treatment across multiple geographies.
• Obalon Therapeutics: Obalon developed a swallowable gas-filled intragastric balloon system. Although the company has faced commercial setbacks, its technology and prior FDA approval make it a historical direct peer in the gas-filled balloon subsegment.

Emerging players

• AspireAssist (Aspire Bariatrics): AspireAssist provided a percutaneous aspiration therapy as a non-surgical weight-loss intervention. It is an emerging adjacent peer offering another endoscopic/procedural alternative to traditional bariatric surgery.
• EndoSphere (endoscopic sleeve gastroplasty providers): EndoSphere offers endoscopic sleeve gastroplasty as a non-surgical alternative for weight loss. It represents an emerging procedural approach overlapping Endalis's endoscopic, non-surgical obesity-treatment category.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/endalis

Compliance10 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Endalis